COMPANY . ABOUT US

ARTEMIS has developed the ArteMice^® platform, a combination of rapid and sophisticated gene vector design, efficient and expert ES cell transfection techniques, novel blastocyst injection techniques and the patented CreER gene switch. Together the ArteMice^® platform makes sophisticated, genetically modified mice for target validation, ADME/T and basic research available faster than ever before.

TaconicArtemis offers the ArteMice^® platform to pharmaceutical and biotechnology companies and to universities. Research groups can access the platform via service agreement, via purchase of tools and reagents and via licensing agreement.

In addition, we have two internal research programs, one dedicated to the development of transgenic approaches to produce animal-wide RNAi knock down in mice in vivo, and the second dedicated to the provision of humanized mouse models for drug testing purposes.

TaconicArtemis is majority owned by Taconic with Exelixis Inc., South San Francisco CA being a minority shareholder. It has a senior management team with over 50 years experience in the pharmaceutical and biotechnology industry. In addition, we have highly skilled group of scientists and technical staff. Senior scientific advisors of the company include Prof. K. Rajewsky (Harvard), Prof. R. Jaenisch (MIT) and Prof. F Stewart (University of Dresden).